Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
04:00:00 2026-10-16 pm EDT
|
5-day change | 1st Jan Change | ||
| 37.00 USD | -2.17% |
|
-0.19% | +20.13% |
| Oct. 16 | Nordic stocks in North America - Ericsson rose 2.6 percent | FW |
| Oct. 15 | Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug | RE |
| Market Cap | 150B 22.5B 20B 18.54B 16.86B 31.82B 2,135B 32.33B 223B 87.35B 1,114B 84.43B 82.63B 3,552B | P/E 2026 * |
30.7x | P/E 2027 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise Value | 169B 25.46B 22.63B 20.97B 19.08B 36.01B 2,416B 36.59B 252B 98.84B 1,261B 95.54B 93.5B 4,019B | EV / Sales 2026 * |
5.69x | EV / Sales 2027 * | 4.6x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Tradegate
| GE91 | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | -2.17% | ||
| 1 week | -0.19% | ||
| Current month | +3.71% | ||
| 1 month | +7.14% | ||
| 3 months | +28.83% | ||
| 6 months | +29.60% | ||
| Current year | +20.13% |
| 1 week | 36.12 |  | 38.33 |
| 1 month | 33.72 | | 40.17 |
| Current year | 23.62 | | 40.17 |
| 1 year | 23.62 | | 40.17 |
| 3 years | 17.24 | | 40.17 |
| 5 years | 17.24 | | 47.5 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 65 | 2020-03-25 |
| Director/Board Member | 75 | 2003-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 66 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -0.19% | - | - | 22.5B | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +9.98% | 22.5B | |
| Average | -1.71% | -0.35% | +45.52% | +94.32% | 41.37B | |
| Weighted average by Cap. | -2.19% | -0.50% | +44.25% | +96.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.72B 4.47B 3.98B 3.68B 3.35B 6.33B 424B 6.43B 44.29B 17.36B 221B 16.78B 16.43B 706B | 35.02B 5.27B 4.68B 4.34B 3.95B 7.45B 500B 7.57B 52.19B 20.46B 261B 19.78B 19.36B 832B |
| Net income | 5.02B 755M 671M 622M 566M 1.07B 71.69B 1.09B 7.48B 2.93B 37.41B 2.83B 2.77B 119B | 7.29B 1.1B 975M 904M 822M 1.55B 104B 1.58B 10.86B 4.26B 54.32B 4.12B 4.03B 173B |
| Net Debt | 19.67B 2.96B 2.63B 2.44B 2.22B 4.19B 281B 4.25B 29.31B 11.49B 147B 11.11B 10.87B 467B | 11.44B 1.72B 1.53B 1.42B 1.29B 2.43B 163B 2.47B 17.05B 6.68B 85.24B 6.46B 6.32B 272B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | $37.00 | -2.17% | 2,684,756 |
| 26-10-15 | $37.82 | +2.52% | 4,084,423 |
| 26-10-14 | $36.89 | +0.88% | 2,687,475 |
| 26-10-13 | $36.57 | -2.14% | 3,736,996 |
| 26-10-12 | $37.37 | +0.81% | 3,127,573 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
